- Previous Close
0.7150 - Open
0.7200 - Bid 0.6189 x 100
- Ask 0.8144 x 100
- Day's Range
0.7011 - 0.7241 - 52 Week Range
0.4950 - 2.1050 - Volume
4,955,928 - Avg. Volume
4,720,040 - Market Cap (intraday)
206.837M - Beta (5Y Monthly) 3.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1900 - Earnings Date Mar 31, 2025 - Apr 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.25
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
www.ocugen.com65
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: OCGN
View More
Performance Overview: OCGN
Trailing total returns as of 2025-01-17, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCGN
View MoreValuation Measures
Market Cap
206.84M
Enterprise Value
174.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.64
Price/Book (mrq)
5.09
Enterprise Value/Revenue
37.22
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.98%
Return on Equity (ttm)
-103.29%
Revenue (ttm)
4.7M
Net Income Avi to Common (ttm)
-51.14M
Diluted EPS (ttm)
-0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
38.7M
Total Debt/Equity (mrq)
16.70%
Levered Free Cash Flow (ttm)
--
Research Analysis: OCGN
View MoreCompany Insights: OCGN
OCGN does not have Company Insights